A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or … (NCT05136677) | Clinical Trial Compass
CompletedPhase 2
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
China102 participantsStarted 2022-01-25
Plain-language summary
The purpose of this study is to assess the efficacy and safety of the combination of nivolumab and ipilimumab in Chinese participants with malignant pleural mesothelioma.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Histologically proven diagnosis of Malignant Pleural Mesothelioma (MPM) with determination of epithelioid vs non-epithelioid histology
* Must have advanced unresectable disease that is not amenable to therapy with curative intent (surgery with or without chemotherapy)
* Available tumor samples for centralized testing
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
* Measurable disease
Exclusion Criteria:
* Primitive peritoneal, pericardial, testis or tunica vaginalis mesothelioma
* Brain metastasis, except if surgically resected or treated with stereotaxic radiotherapy
* Prior therapy for MPM (including chemotherapy, radical pleuropneumonectomy and non-palliative radiotherapy)
Other protocol-defined inclusion/exclusion criteria apply